rs7528684

Meta-analysis of nine case-control studies (2,544 patients, 3,913 controls) examining the FCRL3 -169 C/T polymorphism (rs7528684) and systemic lupus erythematosus (SLE) found no significant association overall (OR = 0.999, 95% CI = 0.925-1.080, p = 0.986) or in European and Asian subgroups. The polymorphism does not appear to confer SLE susceptibility in these populations, despite earlier findings in a Japanese population.

This genome-wide association study identifies genetic loci associated with zinc transporter 8 autoantibodies (ZnT8A) positivity in 2,239 type 1 diabetes cases. The FCRL3 locus on chromosome 1 (rs7522061 T>C, p=1.13×10⁻¹⁶, OR=1.82) and HLA class I region (rs9258750 A>G, p=2.06×10⁻⁹) show strong associations with ZnT8A. The SLC30A8 rs13266634 (R325W) shows epitope-specific associations: strong association with ZnT8WA (p=9.26×10⁻²⁷) and negative association with ZnT8RA (p=7.20×10⁻¹⁷). Notably, these ZnT8A-associated loci do not alter type 1 diabetes risk, indicating ZnT8A is a downstream biomarker rather than primary pathogenic factor.

The FCRL3 -169C>T SNP (rs7528684) in the promoter region of the FCRL3 gene shows a dose-dependent effect on FCRL3 protein expression in B cells, with CC homozygotes expressing significantly higher levels than TT homozygotes (p < 0.0001) in both healthy donors and SLE patients. However, in contrast to prior association in Japanese populations, meta-analysis of four published studies found no significant association between this SNP and SLE in European Americans (N=2,220, OR=1.0478, p=0.45) or pan-Asian groups (N=4,267, OR=1.0616, p=0.412), suggesting ethnic-specific genetic effects.

This study examined hemolytic anemia in 628 SLE patients from the LUMINA multiethnic cohort, analyzing associations with FCGR and Fas/FasL polymorphisms and clinical outcomes. Key findings: FCGR2B-I131T, FasL-205, and FasL-844 polymorphisms showed association with hemolytic anemia; independent risk factors for hemolytic anemia included African American ethnicity (OR 4.21), thrombocytopenia (OR 2.38), and azathioprine use (OR 2.25). Hemolytic anemia was associated with damage accrual but not mortality.